Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 9/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.45 |
| ▸ | INSR | P06213 | 6/20 | 0.45 |
| ▸ | JAK2 | O60674 | 6/20 | 0.44 |
| ▸ | AURKA | O14965 | 5/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.44 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
| ▸ | FYN | P06241 | 3/20 | 0.44 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | FLT1 | P17948 | 3/20 | 0.44 |
| ▸ | LTK | P29376 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.44 |
| ▸ | CLK2 | P49760 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919239 | 0.90 | AURKA (0.44) | IGF1RALKAURKAJAK3BTK | |
| SCHEMBL15498401 | 0.82 | STK17B (0.47) | IGF1RALKINSRJAK2AURKA | |
| SCHEMBL11916403 | 0.78 | JAK2 (0.63) | IGF1RALKINSRJAK2AURKA | |
| SCHEMBL3339774 | 0.75 | JAK2 (0.42) | IGF1RALKJAK2AURKANTRK1 | |
| SCHEMBL11916315 | 0.73 | ALK (0.53) | IGF1RALKINSRAURKAPTK2 | |
| SCHEMBL19203805 | 0.73 | ALK (0.53) | IGF1RALKINSRAURKAPTK2 | |
| SCHEMBL4071017 | 0.72 | NTRK1 (0.74) | IGF1RALKJAK2AURKANTRK1 | |
| SCHEMBL11901091 | 0.72 | ALK (0.73) | IGF1RALKINSRPTK2CDK7 | |
| SCHEMBL11916378 | 0.71 | AURKA (0.47) | ALKAURKAPTK2WEE1GSK3A | |
| SCHEMBL1491753 | 0.71 | AURKA (0.46) | IGF1RALKINSRJAK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | IGF1R 526/4885ALK 256/4885INSR 941/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | IGF1R 586/4885ALK 265/4885INSR 985/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | IGF1R 477/4885ALK 370/4885INSR 751/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | IGF1R 586/4885ALK 265/4885INSR 985/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | IGF1R 526/4885ALK 256/4885INSR 941/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | IGF1R 543/4885ALK 316/4885INSR 767/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | IGF1R 543/4885ALK 316/4885INSR 767/4885 |
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | IGF1R 526/4885ALK 256/4885INSR 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.